Consensus EirGenix Inc.

Equities

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-06-27 EDT			5-day change	1st Jan Change
90.5 ^TWD	+2.84%		+4.50%	-9.95%

06-14	Sandoz AG Re-Submits the Biosimilar Drug EG12014 (Trastuzumab Biosimilar) 150 Mg Powder BLA to the US FDA	CI
05-15	EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

f5f5f2c04.iCt8UsjUzWhWG6Ww8Vw-leiJE1_GQWmP_jfIsuIdzv8.vWgsP56MmTpnf5HRpWxM_tq5aTiOLhDVjXqv5atnhsr8Xi4UnYSvMTUinQ~c7194e1f5234518472f0c1aa8bdb6b9f

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

90.5 TWD

Average target price

112.5 TWD

Spread / Average Target

+24.31%

High Price Target

135 TWD

Spread / Highest target

+49.17%

Low Price Target

90 TWD

Spread / Lowest Target

-0.55%

Trading Rating

Investor Rating

ESG Refinitiv